This study aimed to systematically assess the impact of psychotropic medication-induced sexual dysfunction on all sexes and to outline the safety of relevant medical interventions. Several databases were searched using key terms to derive pertinent data across randomly selected population groups. Viable literature was screened using eligibility criteria, selecting the most vital and reliable information. Conflicting information and heterogeneity across studies required a systematic narrative to represent the included data. A bias risk summary was calculated using the Cochrane Tool for Risk of Bias calculation. Our search yielded more than 2000 eligible studies. Further stratification was performed to eliminate non-pertinent data, and characteristics of selected studies were tabulated. Selective serotonin reuptake inhibitors (SSRIs) and typical antipsychotics were strongly associated with sexual dysfunction across various study populations. Switching from SSRIs to serotonin-norepinephrine reuptake inhibitors and/or switching from prolactin-raising antipsychotic psychotropic medication was associated with improved sexual function. Pharmacological interventions were suggested by a majority of the included studies. Non-pharmacological interventions were associated with improved sexual function across all sexes. Several extracts, including maca root, saffron, and rosa damascene oil, were associated with improved sexual function.